Patents by Inventor Bronwyn G. Siim
Bronwyn G. Siim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150246064Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: May 14, 2015Publication date: September 3, 2015Inventors: David CHAPLIN, Bronwyn G. SIIM
-
Patent number: 9040500Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: GrantFiled: November 28, 2011Date of Patent: May 26, 2015Assignee: OXiGENE, Inc.Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20130136752Abstract: The present disclosure provides novel ophthalmic formulations for ocular administration comprising a pharmaceutically effective amount of a combretastatin, from 60% to 95% w/w pre-gelatinized starch, from 1% to 10% w/w hydrophilic matrix forming polymer, and from 0.2% to 5% lubricant.Type: ApplicationFiled: August 17, 2012Publication date: May 30, 2013Applicant: OXIGENE, INC.Inventors: Suman Sharma, Bronwyn G. Siim
-
Publication number: 20120270831Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: November 28, 2011Publication date: October 25, 2012Applicant: OXIGENE, INC.Inventors: David Chaplin, Bronwyn G. Siim
-
Patent number: 7868040Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and an alkylating agent, which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and cyclophosphamide. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 11, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7868039Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vinca alkaloids, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vincristine. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 11, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7863322Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: March 2, 2004Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7863321Abstract: The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7863320Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a platinum compound which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and carboplatin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Publication number: 20090209496Abstract: This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Receptor Tyrosine Kinase inhibitor (e.g., a small molecule RTK inhibitor, e.g., Sorafenib or Erlotinib) by administering to the subject a Vascular Disrupting Agent (e.g., a Combretastatin or derivative thereof) sequentially or simultaneously in combination with said RTK inhibitor. Pharmaceutical compositions comprising a combination of a RTK inhibitor and a VDA are also provided.Type: ApplicationFiled: February 17, 2009Publication date: August 20, 2009Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20090192098Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: November 21, 2008Publication date: July 30, 2009Applicant: OXIGENE, INC.Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20040204480Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: ApplicationFiled: March 2, 2004Publication date: October 14, 2004Applicant: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim